desloratadine + prednisolone

**Desloratadine + prednisolone** is an oral fixed-dose combination of the second-generation histamine H1 receptor antagonist desloratadine and the synthetic glucocorticoid prednisolone. The studied liquid formulation contains desloratadine 0.5 mg/mL and prednisolone 4 mg/mL and is intended to provide antihistamine symptom control together with corticosteroid-mediated anti-inflammatory activity. It was originated by EMS and subsequently evaluated by Eurofarma in pediatric allergic rhinitis, including a completed Phase 3 trial in children aged 6 to 12 years with moderate-to-severe persistent allergic rhinitis. Earlier randomized pediatric research found efficacy comparable with dexchlorpheniramine + betamethasone, with fewer adverse events such as drowsiness. The broader development program has been reported as discontinued, and no marketed brand specifically for this combination was confirmed. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05214911))

Brand names

DESPRED

Other names

desloratadine + prednisolonedesloratadine associated with prednisolonedesloratadine/prednisoloneDPfixed-dose combination of desloratadine + prednisolone